Genetic modulation of these factors has been shown to improve CD8+ T cell and CAR-T cell function by mitigating exhaustion, enhancing stem-like properties or metabolic adaptability, ultimately leading to tumor regression and extending survival in preclinical models. Here, CD8A is linked to neoplasm.